

PRESS RELEASE



Sanofi & DAP bring World's Leading Diabetes Experts to Pakistan

5th International Diabetes Conference concludes

Karachi, Pakistan – April 5, 2018 Sanofi and the Diabetic Association of Pakistan (DAP) collaborated to bring to Pakistan renowned international diabetes experts from globally recognized centres of academic excellence to address the '5th International Diabetes Conference'.

The conference, now in its fifth consecutive year, was held in 3 cities of Pakistan: Lahore (April 1), Islamabad (April 3) and Karachi (April 5). A cumulative audience of around 700 healthcare professionals attended the conference at the three venues along with a further almost 200 that connected digitally.

The event brought together the following global diabetes experts onto a common platform to share their opinions, insights, perspectives and best practices with healthcare professionals from across Pakistan.

Professor Nam Han Cho

President, International Diabetes Federation (IDF); Professor of Preventive Medicine & Director of Clinical Epidemiology, Ajou University Hospital, South Korea

Professor Massimo Massi Benedetti

President and Scientific Director, Hub for International health ReSearch (HIRS), Italy; Senior Program Advisor, International Diabetes Federation (IDF)

Dr. Dario Rahelic

President, Croatian Society for Diabetes and Metabolic Diseases; Head of Department of Endocrinology, Diabetes and Clinical Pharmacology, Dubrava University Hospital, Croatia

Prof. A. Samad Shera

Secretary General of the Diabetic Association of Pakistan; Honorary President International Diabetes Federation (IDF); Head of World Health Organization (WHO) Collaborating Centre

“Building upon its century long history in the field of Diabetes, Sanofi is committed to improving diabetes management not only through its integrated offering of medicines but also through interactive, medical educational events, scientific workshops and conferences, such as this one”, said Asim Jamal, General Manager and Managing Director of Sanofi Pakistan.

Diabetes is increasing at an alarming rate in Pakistan. According to the IDF Diabetes Atlas (8th edition – 2017) there are currently more than 7.5 million people with diabetes in Pakistan. Secretary General of the Diabetic Association of Pakistan and Honorary President International Diabetes Federation (IDF), Prof. A. Samad Shera, stressed the need for healthier lifestyle and regular screening for diabetes, particularly for those at high risk. *“It is far better to get diagnosed and managed early rather than allow complications to set in before seeking medical advice”*. He also urged to follow the IDF slogan **“Eat less, walk more”**.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Media Relations

Name: Laila Khan

Tel. : +9221 35060221-35

Laila.khan@sanofi.com